Loading clinical trials...

SENSING-AI Cohort for Long COVID Patients | Clinical Trials | Clareo Health

COMPLETED

SENSING-AI Cohort for Long COVID Patients

Prospective Data Collection for SENSING-AI: A Precision Digital and Wearables Platform for the Early Diagnosis of Emotional and Physical Complications in Patients With Long COVID Through the Use of Artificial Intelligence

NCT05204615•Adhera Health, Inc.

View on ClinicalTrials.gov

Summary

The prospective study will focus on the collection of biometric and psychometric data from a limited population for 1 month with the aim of complementing the SENSING-AI retrospective cohort.

Detailed Description

The stratification of the risk of complications related to persistent COVID symptoms both physiological and psychological in a personalized way would optimize the cost-effectiveness model for the management of these patients. Similarly, the early detection of complications associated with persistent COVID in patients belonging to vulnerable groups would improve care times and, therefore, the patient's prognosis. The primary objective of this study is to complement the SENSING-AI cohort with biometric and psychometric data prospectively gathered from patients diagnosed with long COVID in the last year to drive the generation of AI-based risk prediction and stratification models.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Legal adults
•With a long COVID-19 diagnose in the last year
•Reporting any of these symptoms:
•Fatigue
•Dyspnea
•Shortness of breath
•Anxiety
•Stress
•Depression
•Conduct disorder
+1 more criteria

Exclusion Criteria

•Hospital admission during follow-up due to pathology not related to COVID-19
•Patients without digital literacy or who cannot use the mobile application.
•Known severe psychiatric illness or cognitive impairment
•Being pregnant (or suspected to be pregnant)
•Discharged after hospital admission due to COVID-19

Locations (2)

IDIAP Jordi Gol

Barcelona, Spain

Primary Care Aljarafe-Sevilla Norte

Seville, Spain

Key Dates

Start Date

January 18, 2022

Primary Completion Date

February 12, 2022

Completion Date

April 28, 2022

Last Updated

January 5, 2023

Enrollment

ACTUAL participants

Conditions

Post-acute COVID-19 Syndrome

Interventions

Collection of clinical, psychometric and biometric data

OTHER

Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome

NCT05421208

Post-acute COVID-19 SyndromePostural Tachycardia Syndrome (POTS)+2 more

View study

RECRUITINGPHASE2/PHASE3

Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome

NCT05926505

Post-Acute COVID-19 SyndromePost-Acute COVID-19+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 5, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

SENSING-AI Cohort for Long COVID Patients

Inclusion Criteria

Exclusion Criteria

Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome

Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome

Effectiveness of Non-invasive Neuromodulation in Patients With Long-COVID

Cognitive Rehabilitation Therapy for COVID-19

Microbial and Cytokine Signatures in Long COVID Patients

A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid